Literature DB >> 20861671

Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment.

Michael P Lisanti1, Ubaldo E Martinez-Outschoorn, Barbara Chiavarina, Stephanos Pavlides, Diana Whitaker-Menezes, Aristotelis Tsirigos, Agnieszka Witkiewicz, Zhao Lin, Renee Balliet, Anthony Howell, Federica Sotgia.   

Abstract

We have recently proposed a new model for understanding how tumors evolve. To achieve successful "Tumor-Stroma Co-Evolution", cancer cells induce oxidative stress in adjacent fibroblasts and possibly other stromal cells. Oxidative stress in the tumor stroma mimics the effects of hypoxia, under aerobic conditions, resulting in an excess production of reactive oxygen species (ROS). Excess stromal production of ROS drives the onset of an anti-oxidant defense in adjacent cancer cells, protecting them from apoptosis. Moreover, excess stromal ROS production has a "Bystander-Effect", leading to DNA damage and aneuploidy in adjacent cancer cells, both hallmarks of genomic instability. Finally, ROS-driven oxidative stress induces autophagy and mitophagy in the tumor micro-environment, leading to the stromal over-production of recycled nutrients (including energy-rich metabolites, such as ketones and L-lactate). These recycled nutrients or chemical building blocks then help drive mitochondrial biogenesis in cancer cells, thereby promoting the anabolic growth of cancer cells (via an energy imbalance). We also show that ketones and lactate help "fuel" tumor growth and cancer cell metastasis and can act as chemo-attractants for cancer cells. We have termed this new paradigm for accelerating tumor-stroma co-evolution, "The Autophagic Tumor Stroma Model of Cancer Cell Metabolism". Heterotypic signaling in cancer-associated fibroblasts activates the transcription factors HIF1alpha and NFκB, potentiating the onset of hypoxic and inflammatory response(s), which further upregulates the autophagic program in the stromal compartment. Via stromal autophagy, this hypoxic/inflammatory response may provide a new escape mechanism for cancer cells during anti-angiogenic therapy, further exacerbating tumor recurrence and metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861671      PMCID: PMC3040943          DOI: 10.4161/cbt.10.6.13370

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  49 in total

1.  Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway.

Authors:  Takao Ide; Yoshihiko Kitajima; Atsushi Miyoshi; Takao Ohtsuka; Mayumi Mitsuno; Kazuma Ohtaka; Yasuo Koga; Kohji Miyazaki
Journal:  Int J Cancer       Date:  2006-12-15       Impact factor: 7.396

2.  HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis.

Authors:  Barbara Chiavarina; Diana Whitaker-Menezes; Gemma Migneco; Ubaldo E Martinez-Outschoorn; Stephanos Pavlides; Anthony Howell; Herbert B Tanowitz; Mathew C Casimiro; Chenguang Wang; Richard G Pestell; Philip Grieshaber; Jaime Caro; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2010-09-04       Impact factor: 4.534

3.  Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care--correlations with food intake, metabolism, exercise capacity, and hormones.

Authors:  Marita Fouladiun; Ulla Körner; Ingvar Bosaeus; Peter Daneryd; Anders Hyltander; Kent G Lundholm
Journal:  Cancer       Date:  2005-05-15       Impact factor: 6.860

4.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

5.  Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats.

Authors:  Esther Barreiro; Beatriz de la Puente; Sílvia Busquets; Francisco J López-Soriano; Joaquim Gea; Josep M Argilés
Journal:  FEBS Lett       Date:  2005-03-14       Impact factor: 4.124

6.  Molecular mechanisms of resistance to tumour anti-angiogenic strategies.

Authors:  Renaud Grépin; Gilles Pagès
Journal:  J Oncol       Date:  2010-03-09       Impact factor: 4.375

Review 7.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

8.  Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.

Authors:  Giovanni Mantovani; Clelia Madeddu; Giulia Gramignano; Maria Rita Lusso; Miria Mocci; Elena Massa; Luca Ferreli; Giorgio Astara; Antonio Macciò; Roberto Serpe
Journal:  J Exp Ther Oncol       Date:  2003 Jul-Aug

9.  Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer.

Authors:  Agnieszka K Witkiewicz; Abhijit Dasgupta; Katherine H Nguyen; Chengbao Liu; Albert J Kovatich; Gordon F Schwartz; Richard G Pestell; Federica Sotgia; Hallgeir Rui; Michael P Lisanti
Journal:  Cancer Biol Ther       Date:  2009-06-29       Impact factor: 4.742

10.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

View more
  85 in total

Review 1.  Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Alexander Scarth Watson; Monika Mortensen; Anna Katharina Simon
Journal:  Cell Cycle       Date:  2011-06-01       Impact factor: 4.534

Review 2.  Targeting lactate metabolism for cancer therapeutics.

Authors:  Joanne R Doherty; John L Cleveland
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

3.  Monocarboxylate transporter 1 inhibitors as potential anticancer agents.

Authors:  Shirisha Gurrapu; Sravan K Jonnalagadda; Mohammad A Alam; Grady L Nelson; Mary G Sneve; Lester R Drewes; Venkatram R Mereddy
Journal:  ACS Med Chem Lett       Date:  2015-03-19       Impact factor: 4.345

4.  Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics.

Authors:  Ubaldo E Martinez-Outschoorn; Marco Prisco; Adam Ertel; Aristotelis Tsirigos; Zhao Lin; Stephanos Pavlides; Chengwang Wang; Neal Flomenberg; Erik S Knudsen; Anthony Howell; Richard G Pestell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2011-04-15       Impact factor: 4.534

Review 5.  Endothelial cell metabolism in normal and diseased vasculature.

Authors:  Guy Eelen; Pauline de Zeeuw; Michael Simons; Peter Carmeliet
Journal:  Circ Res       Date:  2015-03-27       Impact factor: 17.367

6.  Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis: the seed and soil also needs "fertilizer".

Authors:  Michael P Lisanti; Ubaldo E Martinez-Outschoorn; Zhao Lin; Stephanos Pavlides; Diana Whitaker-Menezes; Richard G Pestell; Anthony Howell; Federica Sotgia
Journal:  Cell Cycle       Date:  2011-08-01       Impact factor: 4.534

Review 7.  Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence.

Authors:  Sarah Crawford
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

8.  Can metabolomics in addition to genomics add to prognostic and predictive information in breast cancer?

Authors:  Anthony Howell
Journal:  BMC Med       Date:  2010-11-16       Impact factor: 8.775

9.  Stem cell marker-positive stellate cells and mast cells are reduced in benign-appearing bladder tissue in patients with urothelial carcinoma.

Authors:  Björn L Isfoss; Christer Busch; Helena Hermelin; Anette T Vermedal; Marianne Kile; Geir J Braathen; Bernard Majak; Aasmund Berner
Journal:  Virchows Arch       Date:  2014-02-26       Impact factor: 4.064

10.  MicroRNA-137 is a novel hypoxia-responsive microRNA that inhibits mitophagy via regulation of two mitophagy receptors FUNDC1 and NIX.

Authors:  Wen Li; Xingli Zhang; Haixia Zhuang; He-ge Chen; Yinqin Chen; Weili Tian; Wenxian Wu; Ying Li; Sijie Wang; Liangqing Zhang; Yusen Chen; Longxuan Li; Bin Zhao; Senfang Sui; Zhe Hu; Du Feng
Journal:  J Biol Chem       Date:  2014-02-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.